sub:assertion {
d:DB00736 dv:ddi-interactor-in dr:DB00736_DB00758 .
d:DB00758 dv:ddi-interactor-in dr:DB00736_DB00758 .
dr:DB00736_DB00758 dcterms:identifier "drugbank_resource:DB00736_DB00758" ;
dcterms:title "DDI between Esomeprazole and Clopidogrel - Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel."@en ;
a dv:Drug-Drug-Interaction ;
rdfs:label "DDI between Esomeprazole and Clopidogrel - Esomeprazole may decrease serum concentrations of the active metabolite(s) of clopidogrel. Due to the possible risk for impaired clopidogrel effectiveness with this combination, clinicians should carefully consider the need for concurrent esomeprazole therapy in patients receiving clopidogrel. Monitor response to clopidogrel closely when using clopidogrel with esomeprazole. Whether there are differences among individual proton pump inhibitors is unclear. Other acid-lowering therapies (e.g., H2-receptor antagonists, antacids, etc.) do not appear to share this interaction with clopidogrel. [drugbank_resource:DB00736_DB00758]"@en .
}